immatics is developing cancer drugs that help to activate the self defense mechanisms of the human body.
Our goal is to support patients and physicians with new options in the fight against various cancers.
Our means are synthetic peptides that specifically activate specialized white blood cells of the patient’s immune system against cancer cells.
Our first product for the treatment of kidney cancer, IMA901, has entered a Europe-wide multi-center Phase II clinical trial in 2007. Our second product for the treatment of colorectal cancer, IMA910, has recently entered another large Phase I/II clinical trial and is now open for patient recruitment.
- -- 05 June 2010
immatics announces Phase II Results with its Therapeutic Cancer Vaccine IMA901 in Patients with Advanced Renal Cell Carcinoma at ASCO - Results of multi-center phase II trial highlight the promise of cancer vaccines in showing strong signal for improved survival ... read more
- -- 05 June 2010
IMA901 data poster presented at ASCO Annual Meeting available for download now! - Posters are now available for download ... read more
- -- 02 June 2010
immatics enters Collaboration with the National Cancer Institute (NCI) to Advance the Development of IMA950 for Glioblastoma - Multi-target therapeutic cancer vaccine IMA950 to enter second clinical phase I study for glioblastoma, the most aggressive ... read more
Renal cell cancer phase II clinical trial
Drug: Peptide-based renal cell cancer vaccine IMA901...read more
Participating countries: Germany, Austria, Switzerland, U.K., Spain, Bulgaria, Hungary, Poland, Romania, Slovakia
Colorectal cancer phase I/II clinical trial
Drug: Peptide-based colorectal cancer vaccine IMA910...read more
Participating countries: Germany, Belgium, U.K., Hungary, Serbia, Latvia, Poland, Romania